Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro

Kunle Odunsi, Paulette Mhawech-Fauceglia, Christopher Andrews, Amy Beck, Olajumoke Amuwo, Shashikant Lele, Jennifer D. Black, Ruea Yea Huang

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Alternatively spliced variants of several oncogenes and tumor suppressors have been shown to be important for their tumorigenicity. In the present study we have tested whether serine-arginine protein kinase 1 (SRPK1), a major regulator of splicing factors, is involved in ovarian cancer progression and plays a role in chemo-sensitivity. By Western blot analyses, SRPK1 protein was found to be overexpressed in 4 out of 6 ovarian cancer cell lines as compared with an immortalized ovarian surface epithelial cell line; and in 55% of ovarian tumor samples as compared with non-neoplastic ovarian tissue samples. Reduction of SRPK1 expression using small interfering RNA (siRNA) encoding small hairpin RNA in ovarian cancer cells led to (i) reduced cell proliferation rate, slower cell cycle progression and compromised anchorage-independent growth and migration ability in vitro, (ii) decreased level of phosphorylation of multiple serine-arginine proteins, and P44/42MAPK and AKT proteins, and (iii) enhanced sensitivity to cisplatin. Together, these results suggest that elevated SRPK1 expression may play a role in ovarian tumorigenesis and SRPK1 may be a potential target for ovarian cancer therapy.

Original languageEnglish (US)
Article numbere51030
JournalPloS one
Volume7
Issue number12
DOIs
StatePublished - Dec 7 2012

Fingerprint

Arginine Kinase
cisplatin
ovarian neoplasms
Cytotoxicity
protein kinases
Ovarian Neoplasms
Protein Kinases
serine
Serine
Cisplatin
Arginine
cytotoxicity
Genes
Proteins
genes
Cells
Small Interfering RNA
Tumors
cell lines
Phosphorylation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Odunsi, K., Mhawech-Fauceglia, P., Andrews, C., Beck, A., Amuwo, O., Lele, S., ... Huang, R. Y. (2012). Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro. PloS one, 7(12), [e51030]. https://doi.org/10.1371/journal.pone.0051030

Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro. / Odunsi, Kunle; Mhawech-Fauceglia, Paulette; Andrews, Christopher; Beck, Amy; Amuwo, Olajumoke; Lele, Shashikant; Black, Jennifer D.; Huang, Ruea Yea.

In: PloS one, Vol. 7, No. 12, e51030, 07.12.2012.

Research output: Contribution to journalArticle

Odunsi, Kunle ; Mhawech-Fauceglia, Paulette ; Andrews, Christopher ; Beck, Amy ; Amuwo, Olajumoke ; Lele, Shashikant ; Black, Jennifer D. ; Huang, Ruea Yea. / Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro. In: PloS one. 2012 ; Vol. 7, No. 12.
@article{7da2473292f54ef382555a9997642c8e,
title = "Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro",
abstract = "Alternatively spliced variants of several oncogenes and tumor suppressors have been shown to be important for their tumorigenicity. In the present study we have tested whether serine-arginine protein kinase 1 (SRPK1), a major regulator of splicing factors, is involved in ovarian cancer progression and plays a role in chemo-sensitivity. By Western blot analyses, SRPK1 protein was found to be overexpressed in 4 out of 6 ovarian cancer cell lines as compared with an immortalized ovarian surface epithelial cell line; and in 55{\%} of ovarian tumor samples as compared with non-neoplastic ovarian tissue samples. Reduction of SRPK1 expression using small interfering RNA (siRNA) encoding small hairpin RNA in ovarian cancer cells led to (i) reduced cell proliferation rate, slower cell cycle progression and compromised anchorage-independent growth and migration ability in vitro, (ii) decreased level of phosphorylation of multiple serine-arginine proteins, and P44/42MAPK and AKT proteins, and (iii) enhanced sensitivity to cisplatin. Together, these results suggest that elevated SRPK1 expression may play a role in ovarian tumorigenesis and SRPK1 may be a potential target for ovarian cancer therapy.",
author = "Kunle Odunsi and Paulette Mhawech-Fauceglia and Christopher Andrews and Amy Beck and Olajumoke Amuwo and Shashikant Lele and Black, {Jennifer D.} and Huang, {Ruea Yea}",
year = "2012",
month = "12",
day = "7",
doi = "10.1371/journal.pone.0051030",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro

AU - Odunsi, Kunle

AU - Mhawech-Fauceglia, Paulette

AU - Andrews, Christopher

AU - Beck, Amy

AU - Amuwo, Olajumoke

AU - Lele, Shashikant

AU - Black, Jennifer D.

AU - Huang, Ruea Yea

PY - 2012/12/7

Y1 - 2012/12/7

N2 - Alternatively spliced variants of several oncogenes and tumor suppressors have been shown to be important for their tumorigenicity. In the present study we have tested whether serine-arginine protein kinase 1 (SRPK1), a major regulator of splicing factors, is involved in ovarian cancer progression and plays a role in chemo-sensitivity. By Western blot analyses, SRPK1 protein was found to be overexpressed in 4 out of 6 ovarian cancer cell lines as compared with an immortalized ovarian surface epithelial cell line; and in 55% of ovarian tumor samples as compared with non-neoplastic ovarian tissue samples. Reduction of SRPK1 expression using small interfering RNA (siRNA) encoding small hairpin RNA in ovarian cancer cells led to (i) reduced cell proliferation rate, slower cell cycle progression and compromised anchorage-independent growth and migration ability in vitro, (ii) decreased level of phosphorylation of multiple serine-arginine proteins, and P44/42MAPK and AKT proteins, and (iii) enhanced sensitivity to cisplatin. Together, these results suggest that elevated SRPK1 expression may play a role in ovarian tumorigenesis and SRPK1 may be a potential target for ovarian cancer therapy.

AB - Alternatively spliced variants of several oncogenes and tumor suppressors have been shown to be important for their tumorigenicity. In the present study we have tested whether serine-arginine protein kinase 1 (SRPK1), a major regulator of splicing factors, is involved in ovarian cancer progression and plays a role in chemo-sensitivity. By Western blot analyses, SRPK1 protein was found to be overexpressed in 4 out of 6 ovarian cancer cell lines as compared with an immortalized ovarian surface epithelial cell line; and in 55% of ovarian tumor samples as compared with non-neoplastic ovarian tissue samples. Reduction of SRPK1 expression using small interfering RNA (siRNA) encoding small hairpin RNA in ovarian cancer cells led to (i) reduced cell proliferation rate, slower cell cycle progression and compromised anchorage-independent growth and migration ability in vitro, (ii) decreased level of phosphorylation of multiple serine-arginine proteins, and P44/42MAPK and AKT proteins, and (iii) enhanced sensitivity to cisplatin. Together, these results suggest that elevated SRPK1 expression may play a role in ovarian tumorigenesis and SRPK1 may be a potential target for ovarian cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84870900915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870900915&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0051030

DO - 10.1371/journal.pone.0051030

M3 - Article

C2 - 23236423

AN - SCOPUS:84870900915

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e51030

ER -